AU Patent

AU2019338657A1 — A process for the preparation of Ozanimod and its intermediate (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile

Assigned to Pharmazell GmbH · Expires 2021-03-18 · 5y expired

What this patent protects

The present invention relates to an improved process for preparation of Ozanimod (I) or pharmaceutically acceptable salts thereof. The present invention also relates to an improved process for preparation of (S)-l-amino-2,3-dihydro- 1H-indene-4-carbonitrile (II) or its optically …

USPTO Abstract

The present invention relates to an improved process for preparation of Ozanimod (I) or pharmaceutically acceptable salts thereof. The present invention also relates to an improved process for preparation of (S)-l-amino-2,3-dihydro- 1H-indene-4-carbonitrile (II) or its optically active acid salts.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019338657A1
Jurisdiction
AU
Classification
Expires
2021-03-18
Drug substance claim
No
Drug product claim
No
Assignee
Pharmazell GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.